Our transferrin functionalized, dual-drug loading liposome system effectively delivers FDA-approved TMZ and a bromodomain inhibitor (which is currently in clinical trials for several different types of cancers, including glioma28) to tumors in the brain with the ability to enhance survival and reduce systemic toxicity, reflecting the translational potential to use this platform to deliver novel combination therapies to improve treatment resistance in patients across multiple CNS tumor types. The gene discussed is TF; the disease is cancer.